
---
title: '当代狂犬病疫苗及不断优化的接种方案（3）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=802114'
author: 科学网
comments: false
date: Thu, 04 Nov 2021 01:51:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=802114'
---

<div>   
<p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Italic;color: #333333;letter-spacing: 0;font-size: 32px">当代狂犬病疫苗及不断优化的接种方案（</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 32px">3</span></strong><strong><span style="font-family: Italic;color: #333333;letter-spacing: 0;font-size: 32px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Italic;color: #333333;letter-spacing: 0;font-size: 32px"><br></span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:64px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">本文主要取材于今年</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">6月出版的专业杂志《</span></strong><strong><span style="font-family: KaiTi;color: #C00000;letter-spacing: 0;font-size: 24px">Viruses</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">》</span> 上的一篇综述论文（见参考文献），原文的两位作者来自美国堪萨斯州立大学（曼哈顿），该大学是国际著名的狂犬病研究机构之一。该文的3位审稿人分别是美国CDC主管狂犬病研究的现负责人和前负责人，以及美国农业部主管狂犬病问题的负责人。</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:64px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">本文提供的权威资料可帮助公众更深入认识狂犬病和狂犬病疫苗：知道如何判断狂犬病疫苗的有效性，了解狂犬病疫苗接种方案不断优化的历程和未来发展趋势。</span></strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px"> </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:55px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: SimSun;color: #2E3033;letter-spacing: 0;font-weight: bold;font-size: 24px">2. </span><strong><span style="font-family: SimSun;color: #2E3033;letter-spacing: 0;font-size: 24px">数据比较</span></strong><strong><span style="font-family: SimSun;color: #2E3033;letter-spacing: 0;font-size: 24px">（续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:55px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">2．1．免疫</span></strong><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">原性（早先已发布）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:55px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">2.   2.  有效性</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:55px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">2．3.  记忆反应</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">－</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">2. 2.  有效性（Efficacy ）</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">证明一种新提出的</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PEP</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（暴露后预防</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">方案的有效性是非常重要的，原因显而易见。只有在</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">免疫原性</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">immunogenicity</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">得到证实后，才能进行临床试验以证明其有效性。在进行临床试验以证明有效性时，重要的是能够从</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">的动物中收集诊断样本</span>(即脑组织)，并将它们提交给可靠的狂犬病诊断实验室，以确认动物患了狂犬病。第一次证明</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">HDCV</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">(</span></span><span style="text-decoration:underline;"><span style="font-family: SimSun;line-height: 200%;font-size: 19px">人二倍体细胞狂犬病疫苗</span></span><span style="font-family: SimSun;line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">有效性的现场试验是在</span>1975年至1976年期间在伊朗进行的，涉及被证实患有狂犬病的狼和狗咬伤的45名患者。44例患者同时接受抗狂犬病血清治疗。一个暴露于气溶胶狂犬病的病人没有给予抗狂犬病血清。</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">皮下</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> subcutaneously</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">注射六</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">HDCV</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">后</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">，所有患者都存活下来，证明</span>HDCV是有效的，可以预防</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露于</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">患者</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">发</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">病。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">通过</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">ID</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（皮内</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">途径</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">接种</span>CCV</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">也需要证明其安全性和有效性。第一个调查</span>ID PEP疗效的研究是在泰国进行的，包括58</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">名</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">患者。这项研究包括</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">轻微暴露于</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病动物的患者。研究人员检查了接种疫苗后的</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">RVNA</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（狂犬病毒中和抗体</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">反应，以及接受三种</span>ID PEP方案之一的患者的生存率，并与</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">WHO</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">推荐的五</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">IM</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（肌肉内</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> PEP方案进行了比较。所有患者在第14天和第35天(抽取血液进行检测的最后一天)存活下来，中和抗体滴度</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">都</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">超过</span>0.5 IU/mL。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">上述</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">由</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">Phanuphak及其同事进行的</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">ID</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（皮内</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> PEP研究在Chutivongse等人在泰国进行的第二项研究中得到了证实。第二项研究招募了100名被</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">已</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">确诊为狂犬病</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">动物严重咬伤的患者，所有患者在接种疫苗后随访一年。所有患者在注射最后一剂疫苗一年后被确认存活。这两项最初的疗效研究提供了根据上述时间表给予</span>ID PEP时，与IM PEP同样有效所需的证据，并</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">可</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">作为设计额外</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">临床试验</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">以</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">评估新的</span>PEP方案有效性的模型。进一步的临床研究证实，其他经</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">WHO</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">资格预审的狂犬病疫苗对</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">IM</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（肌肉内）</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> PEP和</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">ID</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（皮内</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> PEP也都是安全有效的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">2. 3.  记忆反应</span></strong><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">（</span></strong><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">Anamnestic Response </span></strong><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">）</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">显然，</span>PEP和</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PreP</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（暴露前预防</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">都是保护有感染狂犬病风险的人的有效策略。然而，</span>PEP和PreP后达到预防疾病的方法是不同的。证明PEP后出现</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">记忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">反应不是首要目标，然而，这是暴露于狂犬病风险较高的人接受预防接种的两个基本原因之一。进行预防接种是为了确保接种过疫苗的人在未来暴露于狂犬病的情况下，能够对加强疫苗产生快速的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">记忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">反应。有几项研究评估并证实了</span><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">通过</span>IM和ID</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">途径接受</span>PreP的患者(</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">包括接受初始</span>PreP系列后10 - 24年)在</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">加强针</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">后出现</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">记忆</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">反应的证据</span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">重要的是，在</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">加强</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">或</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">初次接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">前提取血液样本，以便量化加强</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">前的基线滴度。加强</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">注射后，应在第</span>7 - 10天抽取第二次血液样本，以确定滴度已出现上升，从而确认已发生</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">记忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">反应。</span> </span></p><p style="line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 24px">3.</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 24px">结论</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">CCV在预防死亡和改变预防人类狂犬病的公共卫生策略中的作用</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">再怎么强调也</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">不</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">算过份</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。如果最初使用</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">CCV来对</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">人</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">进行</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PEP的漫长</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">且</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">昂贵的疫苗接种方案保持不变，各国政府很可能就不会有及时更换</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">NTV（神经组织疫苗</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的动力。正如本文所讨论的，过去四</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">十</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">年</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">里进行了大量</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">临床试验</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">一直在</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">研究如何以</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">缩短</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">疫苗接种方案</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">来进行狂犬病的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PEP和PreP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。大量</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">临床试验的结果导致</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">存在</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">大量</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">已</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">发布</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的累积的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">数据</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">政府卫生机构</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">为了使</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">他们国家</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的民众更容易</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">获得狂犬病生物制品</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，需要</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">尝试比较不同</span>IM和ID方案</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的优劣和可行性，但这种比较</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">是一个</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">非常</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">艰巨的任务。</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">然而</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">在就</span>PEP和PreP方案</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">提出</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">国家建议时，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">如果重点</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">关注</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">前述</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">三个</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">可</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">作为等效基准的具体标准，已公布的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">看似过量的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">临床数据也可以成为宝贵的信息来源。这些证据包括</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">：</span>1）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">开始接种疫苗后特定时间</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">疫苗</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">免疫原性的证据，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">2）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露于狂犬病毒后</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">疫苗</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">有效性的证据，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">3）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">确定新方案</span>/</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">新</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">疫苗对加强接种可产生快速</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">记忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">反应的事实。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:49px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">（</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">全文</span></strong><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 21px">完）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">参考文献：</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">Briggs, D.J.; Moore, S.M. </span><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">The Route of Administration of Rabies Vaccines: Comparing the Data. </span></strong><em><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">Viruses</span></em><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px"> 2021, 13, 1252.  </span><a href="https://www.mdpi.com/1999-4915/13/7/1252" target="_blank"><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';color: #6666CC;letter-spacing: 0;font-size: 19px">https://www.mdpi.com/1999-4915/13/7/1252</span></span></a><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">   </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 24px">相关博文：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1310423" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=802114" title alt="image.png" referrerpolicy="no-referrer"> 当代狂犬病疫苗及不断优化的接种方案（1）</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2021-11-01</span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 16px">。</span></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 28px; background: rgb(255, 255, 255);"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=802115" title alt="image.png" referrerpolicy="no-referrer">  <a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1310513" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 16px"><span style="font-family:Tahoma">当代狂犬病疫苗及不断优化的接种方案（</span>2）</span></span></strong></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 16px"> 2021-11-02</span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 16px">。</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1310808.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1310808.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1310513.html" target="_black">当代狂犬病疫苗及不断优化的接种方案（2）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            